# US 2019/0290587 A1 · Pulsatile drug delivery system for treating morning akinesia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0290587 A1
- Document ID: US20190290587A1
- Status: Published application
- Kind: A1
- Application number: 16/316,698
- Filed: 2017-07-11
- Published: 2019-09-26
- Earliest claimed: 2016-07-11
- Assignees: Contera Pharma Aps; Solural Pharma ApS
- Applicants: Contera Pharma ApS; Solural Pharma ApS
- Inventors: John Bondo Hansen; Mikael Søndergård Thomsen; Ann Vivian Fullerton; Bent Højgaard; Peter Gudmund Nielsen
- Web page: https://patentgrep.com/patent/US20190290587A1

## CPC

- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.

## Claims

### Claim 1

A pulsatile release pharmaceutical composition comprising
i) levodopa and a DOPA decarboxylase inhibitor, and
ii) a pulsatile release component providing for a predetermined lag time followed by a pulse release of said levodopa and said DOPA decarboxylase inhibitor.

### Claim 2

A pulsatile release pharmaceutical composition comprising, separately or together,
i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing for a predetermined lag time followed by a pulse release of levodopa, and
ii) a second pulsatile release component comprising a DOPA decarboxylase inhibitor, said second pulsatile release component providing for a predetermined lag time followed by a pulse release of said DOPA decarboxylase inhibitor.

### Claim 3

A pulsatile release pharmaceutical composition comprising, separately or together,
i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing for a predetermined lag time followed by a pulse release of levodopa, and
ii) a second pulsatile release component comprising a DOPA decarboxylase inhibitor, said second pulsatile release component providing for a predetermined lag time followed by a pulse release of said DOPA decarboxylase inhibitor,
wherein the lag time of said first pulsatile release component comprising levodopa is longer than the lag time of said second pulsatile release component comprising a DOPA decarboxylase inhibitor.

### Claim 4

The pharmaceutical composition according to any of the preceding claims, wherein said DOPA decarboxylase inhibitor is selected from the group consisting of carbidopa, benserazide, methyldopa and DFMD (α-Difluoromethyl-DOPA), or a pharmaceutically acceptable derivative thereof.

### Claim 5

The pharmaceutical composition according to any of the preceding claims, wherein said levodopa comprises pharmaceutically acceptable derivatives of levodopa, including but not limited to levodopa pro-drugs such as levodopa methyl ester and XP21279; and modified levodopa such as deuterated levodopa.

### Claim 6

The pharmaceutical composition according to any of the preceding claims, wherein said pulsatile release composition is a time controlled pulsatile release system, including bulk-eroding systems and surface-eroding systems.

### Claim 7

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition is a pharmaceutical dosage form.

### Claim 8

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical dosage form is a solid dosage form, an oral dosage form, and/or an oral solid dosage from.

### Claim 9

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition is a multiparticulate dosage form.

### Claim 10

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition is a multiparticulate dosage form comprising, separately or together, two dosage forms:
i) a first dosage form providing for a predetermined lag time followed by a pulse release of levodopa, and
ii) a second dosage form providing for a predetermined lag time followed by a pulse release of a DOPA decarboxylase inhibitor,
wherein optionally the lag time of said first dosage form comprising levodopa is longer than the lag time of said second dosage form comprising a DOPA decarboxylase inhibitor.

### Claim 11

The pharmaceutical composition according to any of the preceding claims, wherein said multiparticulate dosage form is packaged in a capsule, a pouch a sachet or a stick pack.

### Claim 12

The pharmaceutical composition according to any of the preceding claims, wherein
i) the lag time for the pulsatile release component is adjusted to release said levodopa and said DOPA decarboxylase inhibitor in the small intestine, such as the lower part of the small intestine, and/or
ii) the lag time for the first pulsatile release component comprising levodopa, and the lag time for the second pulsatile release component comprising a DOPA decarboxylase inhibitor, is adjusted to release said levodopa and said DOPA decarboxylase inhibitor in the small intestine, such as the lower part of the small intestine.

### Claim 13

The pharmaceutical composition according to any of the preceding claims, wherein
i) the lag time for the pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor is between 2 to 8 hours; such as 2 to 3 hours, such as 3 to 4 hours, such as 4 to 5 hours, such as 5 to 6 hours, such as 6 to 7 hours, such as 7 to 8 hours,
ii) the lag time for the first pulsatile release component comprising levodopa is between 2 to 8 hours; such as 2 to 3 hours, such as 3 to 4 hours, such as 4 to 5 hours, such as 5 to 6 hours, such as 6 to 7 hours, such as 7 to 8 hours, and/or
iii) the lag time for the second pulsatile release component comprising a DOPA decarboxylase inhibitor is between 2 to 8 hours; such as 2 to 3 hours, such as 3 to 4 hours, such as 4 to 5 hours, such as 5 to 6 hours, such as 6 to 7 hours, such as 7 to 8 hours.

### Claim 14

The pharmaceutical composition according to any of the preceding claims, wherein the lag time of the first dosage form comprising levodopa is 5 minutes to 90 minutes longer than the lag time of the second dosage form comprising a DOPA decarboxylase inhibitor; such as 5 to 10 minutes longer, such as 10 to 15 minutes longer, such as 15 to 20 minutes longer, such as 20 to 25 minutes longer, such as 25 to 30 minutes longer, such as 30 to 35 minutes longer, such as 35 to 40 minutes longer, such as 40 to 45 minutes longer, such as 45 to 50 minutes longer, such as 50 to 55 minutes longer, such as 55 to 60 minutes longer, such as 60 to 65 minutes longer, such as 65 to 70 minutes longer, such as 70 to 75 minutes longer, such as 75 to 80 minutes longer, such as 80 to 85 minutes longer, such as 85 to 90 minutes longer than the lag time of the second dosage form comprising a DOPA decarboxylase inhibitor.

### Claim 15

The pharmaceutical composition according to any of the preceding claims, wherein the lag time of the first dosage form comprising levodopa is at least 5 minutes longer than the lag time of the second dosage form comprising a DOPA decarboxylase inhibitor, such as at least 10 minutes longer, such as at least 15 minutes longer, such as at least 20 minutes longer, such as at least 25 minutes longer, such as at least 30 minutes longer, such as at least 35 minutes, such as at least 40 minutes longer, such as at least 45 minutes, such as at least 50 minutes longer, such as at least 55 minutes, such as at least 60 minutes longer than the lag time of the second dosage form comprising a DOPA decarboxylase inhibitor.

### Claim 16

The pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutical composition releases 70 to 100% of the drug load measured at 2 to 5 hours after the lag phase, i.e. releases 70 to 100% of the levodopa and/or the DOPA decarboxylase inhibitor measured at 2 to 5 hours after the lag phase.

### Claim 17

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical dosage form is selected from the group consisting of a tablet, a mini-tablet, a micro-tablet, a sphere, a pellet, a granule and a capsule.

### Claim 18

The pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutical dosage form comprises a coating.

### Claim 19

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical dosage form is selected from the group consisting of a coated tablet, a coated mini-tablet, a coated micro-tablet, a coated sphere, a coated pellet, a coated granule and a coated capsule.

### Claim 20

The pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutical dosage form comprise a soluble core, such as a soluble and swellable core, and a coating.

### Claim 21

The pharmaceutical composition according to any of the preceding claims, wherein the coating is a film coating.

### Claim 22

The pharmaceutical composition according to any of the preceding claims, wherein the coating is an insoluble coating, such as
i) a semi-permeable insoluble coating, or
ii) a rupturable insoluble coating.

### Claim 23

The pharmaceutical composition according to any of the preceding claims, wherein the insoluble coating comprises a film-forming polymer and/or a water-insoluble polymer.

### Claim 24

The pharmaceutical composition according to any of the preceding claims, wherein the semi-permeable insoluble coating comprises a water-insoluble polymer and a pore-former, such as a hydrophilic pore former.

### Claim 25

The pharmaceutical composition according to any of the preceding claims, wherein the ratio in the coating of the film-forming or water-insoluble polymer and the hydrophilic pore-former is approx. 10/90, 15/85, 20/80, 25/75 or 30/70.

### Claim 26

The pharmaceutical composition according to any of the preceding claims, wherein the film-forming polymer and/or a water-insoluble polymer is selected from the group consisting of ethylcellulose, hydroxypropyl cellulose, cellulose acetate, acrylic polymers, enteric polymers, hypromellose acetate succinate, shellac, vax and ethylcellulose dispersions.

### Claim 27

The pharmaceutical composition according to any of the preceding claims, wherein the pore-former is selected from the group consisting of polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG).

### Claim 28

The pharmaceutical composition according to any of the preceding claims, wherein the coating is a soluble coating.

### Claim 29

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical dosage form comprises coated tablets comprising levodopa and/or a DOPA decarboxylase inhibitor providing for a predetermined lag time followed by a pulse release of said levodopa and said DOPA decarboxylase inhibitor.

### Claim 30

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition is a multiparticulate dosage form comprising, separately or together,
i) coated tablets comprising levodopa providing for a predetermined lag time followed by a pulse release of levodopa, and
ii) coated tablets comprising a DOPA decarboxylase inhibitor providing for a predetermined lag time followed by a pulse release of a DOPA decarboxylase inhibitor,
wherein optionally the lag time of said coated tablets comprising levodopa is longer than the lag time of said coated tablets comprising a DOPA decarboxylase inhibitor.

### Claim 31

The pharmaceutical composition according to any of the preceding claims, wherein said coated tablets are coated mini-tablets.

### Claim 32

The pharmaceutical composition according to any of the preceding claims, wherein said coated mini-tablets are compressed to form a tablet.

### Claim 33

The pharmaceutical composition according to any of the preceding claims, wherein said dosage form comprises or consists of a core and a coating, said core comprising
i) levodopa and/or a DOPA decarboxylase inhibitor,
ii) a superdisintegrant,
iii) one or more excipients, and
iv) optionally an anti-adherent.

### Claim 34

The pharmaceutical composition according to any of the preceding claims, wherein said first pulsatile release component is a coated mini-tablet comprising
a mini-tablet core comprising or consisting of
i) 25 to 75% w/w levodopa; such as 25 to 30%, such as 30 to 35%, such as 35 to 40%, such as 40 to 45%, such as 45 to 50%, such as 50 to 55%, such as 60 to 65%, such as 65 to 70%, such as 70 to 75% w/w levodopa,
ii) 15 to 50% w/w superdisintegrant; such as 15 to 20%, such as 20 to 25%, such as 25 to 30%, such as 30 to 35%, such as 35 to 40%, such as 40 to 45%, such as 45 to 50% w/w superdisintegrant,
iii) 10 to 50% w/w excipients; such as 10 to 15%, such as 15 to 20%, such as 20 to 25%, such as 25 to 30%, such as 30 to 35%, such as 35 to 40%, such as 40 to 45%, such as 45 to 50% w/w excipients, and
iv) 0 to 2% w/w anti-adherent; such as 0.25 to 0.50% w/w anti-adherent, such as 0.50 to 0.75%, such as 0.75 to 1.0%, such as 1.0 to 1.25, such as 1.25 to 1.50, such as 1.50 to 1.75%, such as 1.75 to 2.0% w/w anti-adherent, and
a coating.

### Claim 35

The pharmaceutical composition according to any of the preceding claims, wherein said mini-tablet core comprises 1 to 5 mg levodopa, such as 1 to 1.25 mg, such as 1.25 to 1.5 mg, such as 1.5 to 1.75 mg, such as 1.75 to 2 mg, such as 2 to 2.25 mg, such as 2.25 to 2.5 mg, such as 2.5 to 2.75 mg, such as 2.75 to 3 mg, such as 3 to 3.25 mg, such as 3.25 to 3.5 mg, such as 3.5 to 3.75 mg, such as 3.75 to 4 mg, such as 4 to 4.25 mg, such as 4.25 to 4.5 mg, such as 4.5 to 4.75 mg, such as 4.75 to 5 mg levodopa.

### Claim 36

The pharmaceutical composition according to any of the preceding claims, wherein said second pulsatile release component is a coated mini-tablet comprising
a mini-tablet core comprising or consisting of
i) 25 to 75% w/w DOPA decarboxylase inhibitor; such as 25 to 30%, such as 30 to 35%, such as 35 to 40%, such as 40 to 45%, such as 45 to 50%, such as 50 to 55%, such as 60 to 65%, such as 65 to 70%, such as 70 to 75% w/w DOPA decarboxylase inhibitor,
ii) 15 to 50% w/w superdisintegrant; such as 15 to 20%, such as 20 to 25%, such as 25 to 30%, such as 30 to 35%, such as 35 to 40%, such as 40 to 45%, such as 45 to 50% w/w superdisintegrant,
iii) 10 to 50% w/w excipients; such as 10 to 15%, such as 15 to 20%, such as 20 to 25%, such as 25 to 30%, such as 30 to 35%, such as 35 to 40%, such as 40 to 45%, such as 45 to 50% w/w excipients, and
iv) 0 to 2% w/w anti-adherent; such as 0.25 to 0.50% w/w anti-adherent, such as 0.50 to 0.75%, such as 0.75 to 1.0%, such as 1.0 to 1.25, such as 1.25 to 1.50, such as 1.50 to 1.75%, such as 1.75 to 2.0% w/w anti-adherent, and
a coating.

### Claim 37

The pharmaceutical composition according to any of the preceding claims, wherein said superdisintegrant is selected from the group consisting of Crosslinked starch such as sodium starch glycolate, Crosslinked Cellulose such as croscarmellose sodium and low-substituted hydroxypropylcellulose (L-HPC), Crosslinked PVP (polyvinylpyrrolidone) such as crospovidone, Crosslinked alginic acid, Soy polysaccharides, Calcium silicate, Gellan gum and Xanthan gum.

### Claim 38

The pharmaceutical composition according to any of the preceding claims, wherein said excipients comprise of or more of the group consisting of a binder, wet binder, filler, solid carrier, diluent, flavouring agent, solubilizer, lubricant, glidant, suspending agent, preservative, anti-adherent, wetting agent, disintegrating agent and sorbent or combinations thereof.

### Claim 39

The pharmaceutical composition according to any of the preceding claims, wherein said binder is selected from the group consisting of acacia, alginic acid, carbomers, carboxymethylcellulose sodium, carrageenan, cellulose acetate phthalate, chitosan, copovidone, dextrate, dextrin, dextrose, ethylcellulose, gelatin, guar gum, hydroyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hydroxypropylmethylcellulose (HPMC or hypromellose), methylcellulose, microcrystalline cellulose (MCC), poloxamer, polydextrose, polyethylene oxide, povidone, sodium alginate, sucrose, starch, pregelatinized starch and maltodextrin.

### Claim 40

The pharmaceutical composition according to any of the preceding claims, wherein said excipients comprise a wet binder selected from the group consisting of pregelatinized starch, hydroxypropylmethylcellulose (HPMC), methylcellulose and gelatin.

### Claim 41

The pharmaceutical composition according to any of the preceding claims, wherein said excipients comprise a binder and a wet binder, such as microcrystalline cellulose (MCC) and pregelatinized starch.

### Claim 42

The pharmaceutical composition according to any of the preceding claims, wherein said excipients comprise
i) 5 to 25% w/w binder, such as 5 to 7.5%, such as 7.5 to 10%, such as 10 to 12.5%, such as 12.5 to 15%, such as 15 to 17.5%, such as 17.5 to 20%, such as 20 to 22.5%, such as 22.5 to 25% w/w binder, and
ii) 1 to 20% w/w wet binder, such as 1 to 2.5%, such as 2.5 to 5%, such as 5 to 7.5%, such as 7.5 to 10%, such as 10 to 12.5%, such as 12.5 to 15%, such as 15 to 17.5%, such as 17.5 to 20% w/w wet binder.

### Claim 43

The pharmaceutical composition according to any of the preceding claims, wherein said anti-adherent is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, glyceryl monostearate, hydrogenated castor oil, hydrogenated vegetable oil, medium chain glycerides, palmitic acid, poloxamers, polyethylene glycols, stearic acid and talc.

### Claim 44

The pharmaceutical composition according to any of the preceding claims, wherein said mini-tablet core comprises or consists of
i) 40 to 60% w/w, such as 45 to 55% w/w levodopa,
ii) 20 to 40% w/w, such as 25 to 35% w/w sodium starch glycolate,
iii) 5 to 25% w/w, such as 10 to 20% w/w microcrystalline cellulose,
iv) 1 to 20% w/w, such as 5 to 10% w/w pregelatinized starch, and
v) 0.5 to 1.5% w/w, such as 1% w/w Mg stearate.

### Claim 45

The pharmaceutical composition according to any of the preceding claims, wherein the coating is applied to increase the weight of a mini-tablet core by 10 to 40% w/w, such as 10 to 12.5%, such as 12.5 to 15%, such as 15 to 17.5%, such as 17.5 to 20%, such as 20 to 22.5%, such as 22.5 to 25%, such as 25 to 27.5%, such as 27.5 to 30%, such as 30 to 32.5%, such as 32.5 to 35%, such as 35 to 37.5%, such as 37.5 to 40% w/w.

### Claim 46

The pharmaceutical composition according to any of the preceding claims, wherein the coating is applied to increase the weight of a tablet core by 1 to 20% w/w, such as 1 to 2.5%, such as 2.5 to 5%, such as 5 to 7.5%, such as 7.5 to 10%, such as 10 to 12.5%, such as 12.5 to 15%, such as 15 to 17.5%, such as 17.5 to 20% w/w.

### Claim 47

The pharmaceutical composition according to any of the preceding claims, wherein the weight increase of the coating of the tablet core comprising levodopa, and the weight increase of the coating of the tablet core comprising a DOPA decarboxylase inhibitor, are adjusted in order to release levodopa before the DOPA decarboxylase inhibitor.

### Claim 48

The pharmaceutical composition according to any of the preceding claims, wherein said composition further comprises, separately or together, one or more further active pharmaceutical ingredients.

### Claim 49

The pharmaceutical composition according to any of the preceding claims, wherein said further active pharmaceutical ingredient is selected from the group consisting of dopamine; dopamine receptor agonists such as bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, lisuride, and derivatives thereof; catechol-O-methyl transferase (COMT) inhibitors such as for example tolcapone and entacapone; apomorphine such as apomorphine injection;
NMDA antagonists such as amatidine (Symmetrel); MAO-B inhibitors such as selegiline and rasagiline; serotonin receptor modulators; kappa opioid receptors agonists such as TRK-820 ((E)-N-[17-cyclopropylmethyl)-4, 5α-epoxy-3, 14-dihydroxymorphinan-6β-yl]-3-(furan-3-yl)-N-methylprop-2-enamide monohydrochloride); GABA modulators; modulators of neuronal potassium channels such as flupirtine and retigabine; glutamate receptor modulators; an immediate release product comprising levodopa and a controlled release product comprising levodopa.

### Claim 50

The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition and said further active pharmaceutical ingredient are administered simultaneously, separately or sequentially.

### Claim 51

The pharmaceutical composition according to any of the preceding claims for use in the treatment of morning akinesia in a patient with Parkinson's disease.

### Claim 52

The pharmaceutical composition according to any of the preceding claims for use in the treatment of morning akinesia in a patient with Parkinson's disease, wherein said composition is administered prior to sleep.

### Claim 53

The pharmaceutical composition according to any of the preceding claims for use in the treatment of morning akinesia in a patient with Parkinson's disease, wherein said composition is administered in combination with an immediate release levodopa-product and/or a sustained release levodopa-product.
